UTILIZATION OF RESEARCH ON CARDIOVASCULAR TECHNOLOGIES

心血管技术研究的应用

• 批准号: 3346998
• 负责人: PAUL M WORTMAN
• 金额: $ 18.51万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 1985
• 资助国家: 美国
• 起止时间: 1985-08-01 至 1987-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3346998
• 关键词: cardiovascular disorder; health care service evaluation

New cardiovascular technologies are often embedded in a context of uncertainty and controversy. Given the rapid escalation in costs, the assessment of these technologies for safety and efficacy has taken on added importance. Medical technology assessment typically involves the synthesis of results from multiple research studies. The proposed research seeks to refine further a fundamental part of the assessment process, the synthesis of outcome data from controlled trials. Five syntheses would be conducted on a variety of important medical technologies of both a mature and an emerging nature. The data synthesis approach offers the important advantage of maximizing the information value of previous research at minimal expense. A secondary purpose of the proposed research is to develop a system for quickly and inexpensively archiving and analyzing relevant data from controlled trials and to reduce the usual expense associated with these activities. The data archive and analytic procedures will be stored on a microcomputer system. This will permit the archive to be used by other researchers and clinicians for secondary analysis or to conduct other syntheses of interest to them. The data synthesis approach allows various temporal factors such as the changing nature of the cardiovascular technology, the type of comparison group, and the mix of patients to be monitored and assessed. It is our view that a synthesis system that monitors the relative advantage or disadvantage of a particular technology is valuable for "state of science" activities such as consensus development conferences and for targeting expensive clinical trials or other, smaller funding initiatives. A pilot evaluation study would be conducted to assess the capacity of the system to conduct policy-relevant, timely syntheses. The specific technology will be chosen by NHLBI's Office of Program Planning and Evaluation. Continuous data monitoring also allows the archive to be updated as the results of new clinical trials of a particular cardiovascular technology are published. In addition, findings from emerging technologies can be added to the data archive earlier in the dissemination process so that informed assessment of beneficial, no-difference or harmful outcomes can be made with minimal delay. These would include: hypertension treatments, percutaneous transluminal coronary angioplasty, calcium blockers, coronary care units, and other cardiovascular technology to be selected later.

新的心血管技术通常嵌入在 不确定性和争议。 鉴于成本迅速上升， 对这些技术的安全性和有效性的评估已经增加了 重要性 医疗技术评估通常涉及综合 来自多项研究的结果。 拟议的研究旨在 进一步完善评估进程的一个基本部分，即综合 对照试验的结果数据。 将进行五次综合 在各种重要的医疗技术，既成熟， 新兴的自然 数据综合方法提供了重要的 最大限度地提高以前研究的信息价值的优势， 最低的费用。 拟议研究的第二个目的是开发一个系统， 快速、经济地归档和分析相关数据， 对照试验，并减少与这些相关的通常费用 活动 数据存档和分析程序将存储在 微电脑系统 这将允许其他人使用存档 研究人员和临床医生进行二次分析或进行其他 他们感兴趣的合成物。 数据合成方法允许各种 时间因素，如心血管疾病的性质变化， 技术，比较组的类型，以及患者的混合， 监测和评估。 我们认为， 监控特定技术的相对优势或劣势 对于“科学状态”活动（如共识发展）是有价值的 会议和针对昂贵的临床试验或其他，较小的 筹资举措。 将进行一项试验性评价研究， 系统进行与政策相关的及时综合的能力。 具体的技术将由NHLBI的项目办公室选择 规划和评估。 持续的数据监控还允许存档在 特定心血管技术的新临床试验结果 发表了。 此外，新兴技术的发现可以 在传播过程的早期添加到数据档案中， 对有益、无差异或有害结果的知情评估， 以最小的延迟。 其中包括：高血压治疗， 经皮冠状动脉腔内成形术，钙阻滞剂，冠状动脉 护理单位和其他心血管技术将在稍后选择。